PMID- 26514447
OWN - NLM
STAT- MEDLINE
DCOM- 20160926
LR  - 20151222
IS  - 1876-2026 (Electronic)
IS  - 1876-2018 (Linking)
VI  - 18
DP  - 2015 Dec
TI  - Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) 
      levels in patients of major depressive disorder, treated with fluoxetine and 
      desvenlafaxine.
PG  - 37-41
LID - S1876-2018(15)00232-4 [pii]
LID - 10.1016/j.ajp.2015.10.006 [doi]
AB  - This randomized, open label, prospective, observational study compared clinical 
      efficacy, safety alongwith plasma BDNF levels in outpatients of depression 
      treated with fluoxetine and desvenlafaxine. Patients (aged 18-60 years) with 
      moderate to severe major depressive disorder (MDD) diagnosed by DSM-IV criteria, 
      and Hamilton Rating Scale for Depression (HAM-D) score >/=14, who were prescribed 
      fluoxetine or desvenlafaxine were included (n=30 in each group). Patients were 
      followed up for 12 weeks for evaluation of clinical efficacy, safety along with 
      BDNF levels. In the fluoxetine group, HAM-D scores at the start of treatment was 
      19+/-4.09 which significantly (p<0.05) reduced to 9.24+/-3.98 at 12 weeks. In the 
      desvenlafaxine group, HAM-D scores at the start of treatment was 18+/-3.75 which 
      significantly (p<0.05) reduced to 10+/-3.75 at 12 weeks. The BDNF levels in the 
      fluoxetine group were 775.32+/-30.38pg/ml at the start of treatment which 
      significantly (p<0.05) increased to 850.3+/-24.92pg/ml at 12 weeks. The BDNF levels 
      in the desvenlafaxine group were 760.5+/-28.53pg/ml at the start of treatment which 
      significantly (p<0.05) increased to 845.8+/-32.82pg/ml at 12 weeks. Both the 
      antidepressants were found to be safe and well tolerated. The efficacy and the 
      safety profile of desvenlafaxine is comparable to fluoxetine in patients of MDD. 
      BDNF levels were significantly increased post-treatment with both the 
      antidepressive agents. Whether BDNF may have a prognostic value in predicting 
      treatment response to antidepressant drugs needs to be investigated in a larger 
      patient population.
CI  - Copyright (c) 2015 Elsevier B.V. All rights reserved.
FAU - Ghosh, R
AU  - Ghosh R
AD  - Department of Pharmacology, University College of Medical Sciences & Guru Teg 
      Bahadur Hospital, New Delhi 110095, India.
FAU - Gupta, R
AU  - Gupta R
AD  - Department of Pharmacology, University College of Medical Sciences & Guru Teg 
      Bahadur Hospital, New Delhi 110095, India. Electronic address: 
      drrachna1@rediffmail.com.
FAU - Bhatia, M S
AU  - Bhatia MS
AD  - Department of Psychiatry, University College of Medical Sciences & Guru Teg 
      Bahadur Hospital, New Delhi 110095, India.
FAU - Tripathi, A K
AU  - Tripathi AK
AD  - Department of Biochemistry, University College of Medical Sciences & Guru Teg 
      Bahadur Hospital, New Delhi 110095, India.
FAU - Gupta, L K
AU  - Gupta LK
AD  - Department of Pharmacology, Lady Hardinge Medical College & Smt. S.K. Hospital, 
      New Delhi, India.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20151019
PL  - Netherlands
TA  - Asian J Psychiatr
JT  - Asian journal of psychiatry
JID - 101517820
RN  - 0 (Antidepressive Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 01K63SUP8D (Fluoxetine)
RN  - ZB22ENF0XR (Desvenlafaxine Succinate)
SB  - IM
MH  - Adult
MH  - Antidepressive Agents/administration & dosage/adverse effects
MH  - Brain-Derived Neurotrophic Factor/*metabolism
MH  - *Depressive Disorder, Major/diagnosis/drug therapy/metabolism/psychology
MH  - Desvenlafaxine Succinate/administration & dosage/adverse effects
MH  - Diagnostic and Statistical Manual of Mental Disorders
MH  - Drug Monitoring/methods
MH  - Female
MH  - Fluoxetine/administration & dosage/adverse effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Psychiatric Status Rating Scales
MH  - Treatment Outcome
OTO - NOTNLM
OT  - BDNF
OT  - Depression
OT  - Desvenlafaxine
OT  - Fluoxetine
OT  - MDD
OT  - Open label
EDAT- 2015/10/31 06:00
MHDA- 2016/09/27 06:00
CRDT- 2015/10/31 06:00
PHST- 2015/03/19 00:00 [received]
PHST- 2015/09/13 00:00 [revised]
PHST- 2015/10/04 00:00 [accepted]
PHST- 2015/10/31 06:00 [entrez]
PHST- 2015/10/31 06:00 [pubmed]
PHST- 2016/09/27 06:00 [medline]
AID - S1876-2018(15)00232-4 [pii]
AID - 10.1016/j.ajp.2015.10.006 [doi]
PST - ppublish
SO  - Asian J Psychiatr. 2015 Dec;18:37-41. doi: 10.1016/j.ajp.2015.10.006. Epub 2015 
      Oct 19.